AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1981, the company has established itself as a leader in developing innovative therapies primarily focused on women's health, maternal health, and supportive care. With a strong presence in North America and expanding operations in international markets, AMAG is dedicated to addressing unmet medical needs. The company’s core products, including treatments for iron deficiency anaemia and preterm labour, are distinguished by their commitment to safety and efficacy. AMAG's notable achievements include a robust pipeline of therapies that leverage cutting-edge research and development. As a trusted name in the biopharmaceutical sector, AMAG Pharmaceuticals continues to enhance patient outcomes and solidify its market position through strategic partnerships and a focus on innovation.
DitchCarbon Score
How does AMAG Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AMAG Pharmaceuticals, Inc.'s score of 28 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AMAG Pharmaceuticals, Inc.'s reported carbon emissions
In 2022, AMAG Pharmaceuticals, Inc. reported total carbon emissions of approximately 165.0 kg CO2e, encompassing Scope 1 and 2 emissions. This figure reflects a slight decrease from 2021, when emissions were about 168.0 kg CO2e. The company has not disclosed any Scope 3 emissions data for the years reported. Historically, AMAG's emissions data from 2019 indicates significant Scope 1 emissions of approximately 104,400,000 kg CO2e and Scope 3 emissions of about 1,200,000,000 kg CO2e. However, there are no specific reduction targets or climate pledges outlined in their current commitments. AMAG Pharmaceuticals does not appear to inherit emissions data from any parent or related organisations, and their climate initiatives do not include any SBTi (Science Based Targets initiative) reduction targets or other formal climate pledges. The company continues to monitor and report its emissions, but further commitments or reduction strategies have not been specified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | 104,400,000 | 000,000,000 | 000,000,000 | - | - |
| Scope 2 | - | - | - | - | - |
| Scope 3 | - | - | 0,000,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
AMAG Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
